Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/136754
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Antisense oligonucleotide therapy for KCNT1 encephalopathy |
Author: | Burbano, L.E. Li, M. Jancovski, N. Jafar-Nejad, P. Richards, K. Sedo, A. Soriano, A. Rollo, B. Jia, L. Gazina, E.V. Piltz, S. Adikusuma, F. Thomas, P.Q. Kopsidas, H. Rigo, F. Reid, C.A. Maljevic, S. Petrou, S. |
Citation: | JCI Insight, 2022; 7(23):1-20 |
Publisher: | American Society for Clinical Investigation (ASCI) |
Issue Date: | 2022 |
ISSN: | 2379-3708 2379-3708 |
Statement of Responsibility: | Lisseth Estefania Burbano, Melody Li, Nikola Jancovski, Paymaan Jafar-Nejad, Kay Richards, Alicia Sedo, Armand Soriano, Ben Rollo, Linghan Jia, Elena V. Gazina, Sandra Piltz, Fatwa Adikusuma, Paul Q. Thomas, Helen Kopsidas, Frank Rigo, Christopher A. Reid, Snezana Maljevic, Steven Petrou |
Abstract: | Developmental and epileptic encephalopathies (DEE) are characterized by pharmacoresistant seizures with concomitant intellectual disability. Epilepsy of infancy with migrating focal seizures (EIMFS) is one of the most severe of these syndromes. De novo variants in ion channels, including gain-of-function variants in KCNT1, have been found to play a major role in the etiology of EIMFS. Here, we test a potential precision therapeutic approach in KCNT1-associated DEE using a gene silencing antisense oligonucleotide (ASO) approach. We generated a mouse model carrying the KCNT1 p.P924L pathogenic variant; only the homozygous animals presented with the frequent, debilitating seizures and developmental compromise that are seen in patients. After a single intracerebroventricular bolus injection of a Kcnt1 gapmer ASO in symptomatic mice at postnatal day 40, seizure frequency was significantly reduced, behavioral abnormalities improved, and overall survival was extended compared to mice treated with a control ASO (non-hybridizing sequence). ASO administration at neonatal age was also well-tolerated and effective in controlling seizures and extending the lifespan of treated animals. The data presented here provide proof of concept for ASO-based gene silencing as a promising therapeutic approach in KCNT1-associated epilepsies. |
Keywords: | KCNT1; encephalopathy; epilepsy; ASO; mouse model |
Description: | Published online: 22 November 2022 |
Rights: | © 2022, Burbano et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
DOI: | 10.1172/jci.insight.146090 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/10915693 http://purl.org/au-research/grants/nhmrc/GNT1005050 |
Published version: | http://dx.doi.org/10.1172/jci.insight.146090 |
Appears in Collections: | Genetics publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_136754.pdf | Accepted version | 975.15 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.